Microneedles are central to our solution, but they don’t work alone. Clinically reliable dISF sampling requires a fully integrated system.
Our PELSA system combines precision pressure control to ensure consistent penetration with minimal skin trauma, an integrated microfluidic network to collect and transport dISF, and real-time imaging for continuous quality assurance.
This is complemented by automated sampling protocols developed with our partners to reflect real-world workflows, and a strong focus on safety and biocompatibility through sterile, single-use microneedles.
The needles on each chip are connected using an integrated capillary system that drives the fluid towards a collection reservoir or a sensing element.
The capillaries are designed and manufactured for optimal fluidic properties using a combination of deep reactive ion etching of silicon and anodic glass bonding.
Ascilion currently holds 75+ patents across 12 patent families.
Ascilion has been recognized as being in the top 1% of the 12,000 innovations funded by the EU for our minimally invasive system for dermal interstitial fluid sampling and collection. Furthermore, we have been recognized as a Key Innovator by the EU Innovation Radar for the project “Novel biomarker wearable for interstitial fluid extraction and analysis”.
